KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.85

Pharmacologic de-escalation of dexamethasone during weekly paclitaxel: a randomized phase III trial evaluating safety, endocrine effects, and quality of life.

Vanessa Armenio Scontre, Marcos Tadashi Kakitani Toyoshima, Maria Del Pilar Estevez-Diz

Cancer Chemother Pharmacol 96(1) 75

PMID42439956
PMCIDPMC13364796
DOI10.1007/s00280-026-04920-x
发表日期2026-07-13
入排依据:The trial is a randomized phase III study in human oncology with a drug intervention, but it does not report a primary or key secondary time-to-event efficacy endpoint (like OS, PFS, DFS) with Kaplan-Meier or hazard ratio analysis. The oncologic outcomes mentioned (recurrence and disease-related mortality) are described only as similar in descriptive analyses without formal time-to-event statistical reporting, and the study's primary focus is on safety and quality of life.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:CONSORT/入组流程图;Fig. 3:身体组成变化图;Fig. 4:生活质量量表图。
摘要

摘要

OBJECTIVE: Dexamethasone is routinely used as premedication during weekly paclitaxel to prevent hypersensitivity reactions; however, prolonged corticosteroid exposure may induce clinically relevant metabolic, endocrine, and patient-reported adverse effects. This study evaluated whether selective omission of dexamethasone after the second paclitaxel infusion is safe and explored its effects on quality of life, metabolic/endocrine parameters, and short-term oncologic outcomes, including recurrence and disease-related mortality. METHODS: In this prospective, randomized, open-label phase III trial, 86 women with stage I-III breast cancer receiving neoadjuvant or adjuvant AC-T or AC-TH chemotherapy were randomized 1:1 to standard dexamethasone premedication or omission after the second weekly paclitaxel infusion. The primary endpoint was safety, defined by hypersensitivity reactions and adverse events. Secondary and exploratory endpoints included patient-reported quality of life using the EORTC QLQ-C30, metabolic and endocrine parameters, and short-term oncologic outcomes. Longitudinal changes were analyzed using generalized estimating equations. RESULTS: Eighty-four patients were included in the final analysis. No hypersensitivity reactions occurred after dexamethasone omission, and treatment completion rates were comparable between groups. After a median follow-up of 3.15 years, recurrence and disease-related mortality were similar between groups in descriptive analyses. The omission strategy was associated with improvements in role functioning and reduced worsening of pain (p = 0.02), constipation (p = 0.01), and nausea/vomiting (p = 0.03). No statistically significant differences were observed for emotional or physical functioning. Endocrine analyses demonstrated reduced IGF-1 levels and a trend toward lower insulin levels. These secondary analyses should be interpreted as exploratory. CONCLUSION: Selective omission of dexamethasone after the second weekly paclitaxel infusion was safe and well tolerated in this randomized trial. The findings support the feasibility of a corticosteroid-sparing strategy during weekly paclitaxel and suggest potential benefits in selected patient-reported and endocrine outcomes, which warrant confirmation in larger studies. TRIAL REGISTRATION: NCT04350229, registered on 16 April 2020.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Study design, treatment allocation, and timing of assessments. Patients were randomized 1:1 to standard dexamethasone premedication before every weekly paclitaxel infusion or to dexamethasone omission after the second weekly paclitaxel infusion. Study assessments were performed at three predefined time points: Visit 1 (baseline, before chemotherapy), Visit 2 (before the third weekly paclitaxel infusion), and Visit 3 (24 h after the final paclitaxel infusion). Hypersensitivity reactions and adverse events were monitored throughout all paclitaxel infusions and during the treatment period. QoL was assessed using the EORTC QLQ-C30 at Visits 1, 2, and 3
非 KM Figure
Fig. 2CONSORT flow diagram of patient enrollment, randomization, and analysis
非 KM Figure
Fig. 3Changes in body composition assessed by bioimpedance analysis. Longitudinal changes in body composition parameters between Visit 2 (before the third paclitaxel infusion) and Visit 3 (24 h after the final infusion) in the control and experimental groups. Data include body weight, body mass index (BMI), lean mass, and fat mass. Values are presented as mean changes (delta)
非 KM Figure
Fig. 4Longitudinal changes in quality-of-life domains assessed by the EORTC QLQ-C30 questionnaire. ( A ) Functional scale variations, including emotional, physical, and social (role) functioning, expressed as changes between Visit 2 and Visit 3. ( B ) Symptom scale variations, including pain, nausea and vomiting, constipation, fatigue, insomnia, diarrhea, and dyspnea. Higher scores on functional scales indicate better functioning, whereas higher scores on symptom scales indicate greater symptom burden. Values are presented as mean changes (delta)
非 KM Figure